18 April 2024
Acknowledgement of reviewers 2022–2023
The Editorial team of Tumor Discovery extends its heartfelt thanks to the esteemed scholars who dedicated their time and expertise to peer-review manuscripts during the years 2022 and 2023. Tumor Discovery is committed to advancing oncology research and dissemination of groundbreaking discoveries, and the rigorous peer-review process is integral to achieving this mission. The invaluable efforts of our reviewers have played a crucial role in maintaining the quality and credibility of the journal's publications. The meticulous reviews conducted by these esteemed scholars have ensured the scientific rigor and relevance of the manuscripts considered for publication. Their insightful feedback and constructive criticisms have not only shaped the content of published articles but have also contributed significantly to the advancement of knowledge in the field of tumor biology and oncology. We sincerely thank each reviewer for their commitment and dedication to maintaining the highest standards of academic excellence.  Respectfully Submitted by the Editorial Office of Tumor Discovery
06 February 2024
The Second Online Editorial Board Meeting of Tumor Discovery Successfully Held
The 2nd Online Editorial Board Meeting for Tumor Discovery (TD) was held on January 30, 2024. Hosted by Editor-in-Chief Professor Helmut H. Popper, the meeting brought together esteemed members of the editorial board to summarize the progress made by the journal in 2023, and discuss the future development and strategies for enhancing the visibility and impact of the journal in 2024.                     Key highlights from the meeting include: Warm Welcome and Introductions: Editor-in-Chief Professor Mingzhu Yin welcomed attendees and expressed gratitude to the Editorial Board members (EBMs), authors, reviews, and readers for their continued support. Professor Yin introduced to the members the aims, scope, indexing, and publications.                   2023 Annual Report Presentation: Managing Editor Hannah Zhang presented the 2023 Annual Report of TD, highlighting key activities, achievements, and future initiatives. The report showcased the journal's growing international recognition, indexing status, and efforts to expand readership and citation metrics. Outstanding Contribution Awards: Professor Mingzhu Yin granted Outstanding Contribution Awards to six EBMs, recognizing their significant contributions to TD.                   Development Plan for 2024: Professor Helmut H. Popper outlined strategies to increase the visibility of TD, underscoring the significance of special issues and EBM contributions to further enhance the journal's recognition and reach. Open Discussions and Suggestions: The EBMs actively participated in open discussions, sharing ideas and suggestions to improve the quality, visibility, and collaborative opportunities within the journal. Suggestions ranged from enhancing the quality of case reports to fostering interdisciplinary collaboration. Invitation for Further Collaboration: Attendees were encouraged to provide feedback and suggestions for the continued development and promotion of TD.  Overall, the 2nd Online TD Editorial Board Meeting was marked by fruitful discussions and valuable insights into the future direction of TD. The Editorial Office of TD is grateful to all attendees for their contributions and looks forward to further advancements in oncology research through the journal. Attendee list (in alphabetical order of surnames)Hugo Arias-Pulido, Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.Helmut H. Popper, Department of Pathology, Medical University of Graz, Graz, Austria.Mingzhu Yin, Clinical Research Center (CRC), Medical Pathology Center (MPC), Cancer Early Detection and Treatment Center (CEDTC), Chongqing University Three Gorges Hospital; Translational Medicine Research Center (TMRC), School of Medicine Chongqing University, Chongqing University, Chongqing, China.Steven Brower, Englewood Hospital and Medical Center, Englewood, USA.Shuangqi Cai, Pulmonary and Critical Care Medicine Ward, The First Affiliated Hospital of Guangxi Medical University, China.Lili Cui, Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, China.Jinhai Deng, Kings College London, London, UK.Xinpei Deng, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.Bertani Emilio, Division of Digestive Surgery, European Institute of Oncology IRCCS, Milan, Italy.Luca Ermini, NORLUX Neuro-Oncology Laboratory, Luxembourg Institute of Health, Strassen, Luxembourg.Emilio Hirsch, University of Turin, Turin, Italy.Peter Huppert, Radiologisches Zentrum, Max Grundig Klinik, Bühlerhöhe, Germany.Ilya Klabukov, National Medical Research Radiological Center, Russia.Yifei Liu, Department of Pathology, Affiliated Hospital of Nantong University, China.Tian-Jie Lyu, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.Wenping Ma, Beijing Neurosurgical Institute, Beijing, China.Cioce Mario, Institute of Translational Pharmacology, National Research Council of Italy, Rome, Italy.Gabriela Raso, Department of Translational Molecular Pathology, MD Anderson Cancer Center, Houston, USA.Vishal Shelat, Tan Tock Seng Hospital, Novena, Singapore.Terra Shi, Section Managing Editor of TD.Xiaoyu Shi, The First Affiliated Hospital of Hebei North University, China.Alexander Shtil, Blokhin National Medical Research Center of Oncology, Ministry of Health, Moscow, Russian Federation.Hifzur R Siddique, Aligarh Muslim University, India.Zheng Song, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.Jindong Xie, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.Yan Xu, Department of Endocrinology, Peking University Shougang Hospital, China.Qin Yan, The Department of Pathology, Yale School of Medicine, New Haven, USA.Huike Yang, School of Basic Medical Sciences, Harbin Medical University, China.Hannah Zhang, Managing Editor of TD.Xinyuan Zhao, School of Public Health, Nantong University, Nantong, China.  
07 November 2023
Tumor Discovery was included in the list of journals following the International Committee of Medical Journal Editors (ICMJE) Recommendations
We are pleased to announce that Tumor Discovery (TD, Online ISSN: 2810-9775, Publisher: AccScience Publishing) has been listed as a journal that follows the editorial recommendations of the International Committee of Medical Journal Editors (ICMJE) on October 27, 2023 ( The ICMJE is a small working group of general medical journal editors and representatives of selected related organizations working together to improve the quality of medical science and its reporting. In October 2023, under the application of TD, the ICMJE listed TD as a journal that follows the ICMJE's Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. This gave us great encouragement and confidence to develop TD as a premier, desirable, and transparent international platform for the dissemination of state-of-the-art fundamental and translational studies in tumor research. As an academic publishing platform, TD will continuously comply with the guidelines of Committee on Publication Ethics (COPE), World Association of Medical Editors (WAME), and ICMJE, and endeavor to publish more valuable and scientific research findings to promote scientific innovation.
21 August 2023
Good News: Tumor Discovery is included in CAS Databases
On August 18, 2023, Tumor Discovery (TD, Online ISSN: 2810-9775) had been included in the esteemed database, Chemical Abstracts Service (CAS). This achievement stands as a significant milestone for our journal since its inception in 2022, signifying a remarkable acknowledgment of TD within the global academic community. The CAS database is founded in 1907 as a volunteer effort to organize published chemistry research, CAS officially became a self-supporting division of the American Chemical Society in 1956. CAS is widely acknowledged as the most comprehensive and authoritative source of chemical and scientific research. CAS provides access to over 150 million records from over 100 countries, including patents, scientific articles, and conference proceedings. Please click here to learn more about CAS: The editorial team at TD extends heartfelt gratitude to all esteemed members of the editorial board whose contributions have been instrumental in steering the journal's growth. We extend our appreciation to authors, reviewers, and readers alike for their unwavering support and profound engagement with the journal. Our pledge to provide a valuable platform for groundbreaking tumor research remains unwavering, underscored by our dedication to upholding the highest standards of publishing integrity. It is our aspiration to ascend as a premier international academic journal. TD will continue to uphold rigorous academic standards while publishing more high-quality articles, thereby improving our academic eminence and impact. These efforts are aimed at making greater contributions to academic research and technological innovation.
Back to top
Tumor Discovery, Electronic ISSN: 2810-9775 Published by AccScience Publishing